ArticleEuropean heart journal open2026
Predictors of pacing-induced cardiomyopathy in patients undergoing AV nodal ablation: insights from a Delphi process and retrospective cohort study.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Pacing-induced cardiomyopathy (PICM) is a recognized complication of pace-and-ablate therapy. Early identification of patients at risk may allow tailored strategies, including upfront biventricular or conduction system pacing. Purpose: This study aimed to identify predictors of PICM in patients undergoing pace-and-ablate therapy, combining expert consensus with clinical validation. Methods and results: A three-round Delphi process involving 12 electrophysiologists prioritized candidate predictors of PICM. Consecutive patients undergoing atrioventricular node ablation with non-cardiac resynchronization therapy (CRT) devices at Liverpool Heart and Chest Hospital (2015-2019) were retrospectively analysed. The primary endpoint was PICM, defined as ≥10% reduction in left ventricular ejection fraction (LVEF) to <50%, adjudicated by two independent cardiologists. Cox regression was used to identify independent predictors. The Delphi process prioritized baseline LVEF, intrinsic and paced QRS duration, RV lead position, and key comorbidities. Among 658 ablation patients, 323 (median age 76 years, 67% female) had non-CRT devices. Over a median follow-up of 192 days (IQR, 63-1003 days), 33 patients (9.8%) developed PICM. In multivariable analysis, RV free wall vs. septal lead position [hazard ratio (HR) 4.896, 95% confidence interval (CI) 1.263-18.973, Conclusion: Intrinsic QRS duration and free wall RV lead position independently predict PICM in pace-and-ablate patients. These findings support early risk stratification and may guide personalized pacing strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.